drugset
drugset / Trial / NCT05243524

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

NCT05243524 ↗

Phase 2 Terminated 16 enrolled ImmunoVaccine Technologies, Inc. (IMV Inc.)
NaSingle-groupOpen-labelTreatment

Summary

Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.

Timeline

Start
2022-08-05
Primary completion
2023-07-24
Completion
2023-08-31

Outcome

Outcome not reported

Stopped: “Closure of IMV operations”

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 50 mg Oral

Indications

No indication recorded.